Hematologic Oncology Update

Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma

Sep 14, 2023
Guest
Loretta Nastoupil
Guest
Martin Hutchings
Experts Dr Martin Hutchings and Dr Loretta Nastoupil discuss the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma. Topics include different agents, efficacy, tolerability, dose step up, treatment duration, challenges in generating order sets, patient experience, comparing immunotherapies, and side effect profiles.
Ask episode
Chapters
Transcript
Episode notes
1
Introduction
00:00 • 3min
2
CD20 x CD3 Bispecific Antibodies in Non-Hodgkin Lymphoma Management
03:30 • 13min
3
Challenges of Generating Order Sets and Management of Conditional Toxicity in a New Therapy
16:46 • 4min
4
CD20 x CD3 Bispecific Antibodies in Non-Hodgkin Lymphoma Management
20:59 • 6min
5
Patient Experience and Management of Side Effects
26:47 • 5min
6
Comparing Efficacy and Placement of Immunotherapies in Non-Hodgkin Lymphoma
32:13 • 3min
7
CD20 x CD3 Bispecific Antibodies in Non-Hodgkin Lymphoma Management
35:10 • 26min